A Multicenter, Randomized, Double-blind, Parallel, Placebo-controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of IBI112 in Patients With Moderate to Severe Active Ulcerative Colitis
Latest Information Update: 01 Aug 2024
At a glance
- Drugs Picankibart (Primary) ; Picankibart (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Sponsors Innovent Biologics
Most Recent Events
- 30 Jul 2024 Status changed from recruiting to active, no longer recruiting.
- 24 Nov 2023 Planned End Date changed from 30 Jun 2025 to 30 Sep 2025.
- 24 Nov 2023 Planned primary completion date changed from 30 Dec 2024 to 28 Mar 2024.